Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment

Association, 1987

Biere, 1996, Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma, J. Biol. Chem., 271, 32916, 10.1074/jbc.271.51.32916

Blasko, 2008, Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine, Neurobiol. Aging, 29, 1, 10.1016/j.neurobiolaging.2006.09.002

Blennow, 2003, CSF markers for incipient Alzheimer's disease, Lancet Neurol., 2, 605, 10.1016/S1474-4422(03)00530-1

Blennow, 2006, Alzheimer's disease, Lancet, 368, 387, 10.1016/S0140-6736(06)69113-7

Brun, 1994, Clinical and neuropathological criteria for frontotemporal dementia, J. Neurol. Neurosurg. Psychiatry, 57, 416, 10.1136/jnnp.57.4.416

DeMattos, 2002, Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease, Science, 295, 2264, 10.1126/science.1067568

Erkinjuntti, 2000, Research criteria for subcortical vascular dementia in clinical trials, J. Neurol. Transm. Suppl., 59, 23

Fagan, 2006, Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans, Ann. Neurol., 59, 512, 10.1002/ana.20730

Freeman, 2007, Plasma Abeta levels do not reflect brain Abeta levels, J. Neuropathol. Exp. Neurol., 66, 264, 10.1097/NEN.0b013e31803d3ae4

Fukumoto, 2003, Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels, Arch. Neurol., 60, 958, 10.1001/archneur.60.7.958

Gauthier, 2006, Mild cognitive impairment, Lancet, 367, 1262, 10.1016/S0140-6736(06)68542-5

Gelfanova, 2007, Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry, Brief Funct. Genomic Proteomic, 6, 149, 10.1093/bfgp/elm010

Graff-Radford, 2007, Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease, Arch. Neurol., 64, 354, 10.1001/archneur.64.3.354

Hansson, 2006, Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol., 5, 228, 10.1016/S1474-4422(06)70355-6

Hansson, 2007, Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment, Dement. Geriatr. Cogn. Disord., 23, 316, 10.1159/000100926

Kosaka, 1997, The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42 (43), Neurology, 48, 741, 10.1212/WNL.48.3.741

Kuo, 1999, High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease, Biochem. Biophys. Res. Commun., 257, 787, 10.1006/bbrc.1999.0552

Mayeux, 1999, Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease, Ann. Neurol., 46, 412, 10.1002/1531-8249(199909)46:3<412::AID-ANA19>3.0.CO;2-A

Mayeux, 2003, Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk, Neurology, 61, 1185, 10.1212/01.WNL.0000091890.32140.8F

McKeith, 1999, Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies, Neurology, 53, 902, 10.1212/WNL.53.5.902

McKhann, 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939

Mehta, 2000, Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease, Arch. Neurol., 57, 100, 10.1001/archneur.57.1.100

Mehta, 2001, Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease, Neurosci. Lett., 304, 102, 10.1016/S0304-3940(01)01754-2

Nordlund, 2005, The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition, J. Neurol. Neurosurg. Psychiatry, 76, 1485, 10.1136/jnnp.2004.050385

Oddo, 2004, Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome, Neuron, 43, 321, 10.1016/j.neuron.2004.07.003

Oe, 2006, Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry, Rapid Commun. Mass Spectrom., 20, 3723, 10.1002/rcm.2787

Olsson, 2005, Simultaneous measurement of beta-amyloid (1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology, Clin. Chem., 51, 336, 10.1373/clinchem.2004.039347

Palmer, 2003, Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort study, BMJ, 326, 245, 10.1136/bmj.326.7383.245

Pesaresi, 2006, Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment, Neurobiol. Aging, 27, 904, 10.1016/j.neurobiolaging.2006.03.004

Petersen, 2004, Mild cognitive impairment as a diagnostic entity, J. Int. Med., 256, 183, 10.1111/j.1365-2796.2004.01388.x

Petersen, 1999, Mild cognitive impairment: clinical characterization and outcome, Arch. Neurol., 56, 303, 10.1001/archneur.56.3.303

Pomara, 2005, Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report, Am. J. Geriatr. Psychiatry, 13, 914

Prince, 2004, APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42, Neurology, 62, 2116, 10.1212/01.WNL.0000128088.08695.05

Román, 1993, Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop, Neurology, 43, 250, 10.1212/WNL.43.2.250

Sacuiu, 2005, Prodromal cognitive signs of dementia in 85-year-olds using four sources of information, Neurology, 65, 1894, 10.1212/01.wnl.0000188873.13444.85

Sagare, 2007, Clearance of amyloid-beta by circulating lipoprotein receptors, Nat. Med., 13, 1029, 10.1038/nm1635

Santacruz, 2005, Tau suppression in a neurodegenerative mouse model improves memory function, Science, 309, 476, 10.1126/science.1113694

Scheuner, 1996, Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease, Nat. Med., 2, 864, 10.1038/nm0896-864

Siemers, 2006, Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease, Neurology, 66, 602, 10.1212/01.WNL.0000198762.41312.E1

Sobow, 2005, Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease, Acta Neurobiol. Exp. (Wars), 65, 117, 10.55782/ane-2005-1544

Strozyk, 2003, CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study, Neurology, 60, 652, 10.1212/01.WNL.0000046581.81650.D0

Tamaoka, 1996, Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease, J. Neurol. Sci., 141, 65, 10.1016/0022-510X(96)00143-8

van Oijen, 2006, Plasma Abeta (1-40) and Abeta (1-42) and the risk of dementia: a prospective case-cohort study, Lancet Neurol., 5, 655, 10.1016/S1474-4422(06)70501-4

Vanderstichele, 2000, Standardization of measurement of beta-amyloid (1-42) in cerebrospinal fluid and plasma, Amyloid, 7, 245, 10.3109/13506120009146438

Walsh, 2005, The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention, Biochem. Soc. Trans., 33, 1087, 10.1042/BST0331087

Wiltfang, 2002, Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation, J. Neurochem., 81, 481, 10.1046/j.1471-4159.2002.00818.x

Zetterberg, 2006, Plasma Abeta in Alzheimer's disease—up or down?, Lancet Neurol., 5, 638, 10.1016/S1474-4422(06)70503-8